Generics of AstraZeneca’s oral antiplatelet therapy Brilinta will be released next month.

However, only 6 of the 25 companies that received first generic exclusivity will be releasing actual products. The small number of releases is interpreted to be caused by the domestic companies' declining interest in Brilintagenerics.

According to industry sources on the 22nd, the substance patent for Brilinta will expire on the 20th next month. In other words, generics that had avoided the formulation patent of Brilintawill be allowed to be released from the 21st next month.

Currently, 25 companies have successfully avoided Brillinta’s formulation patent and acquired first generic